Science
Oxford Instruments Unveils Imaris 11 to Transform Image Analysis
On December 1, 2025, Oxford Instruments announced the launch of Imaris 11, a new version of its renowned 3D/4D microscopy image visualization and analysis software. This latest iteration introduces a user-friendly Workflow system, enhanced batch processing, and advanced tools aimed at improving the research process for scientists and researchers across various fields.
Streamlining Research with Innovative Features
The core feature of Imaris 11 is the Workflow system, designed to guide users through image analysis procedures in a clear, step-by-step format. This functionality not only helps novice users navigate complex tasks but also enhances the efficiency of experienced researchers. Workflows can be created, saved, and shared, allowing for easy collaboration and reproducibility across datasets.
Moreover, these workflows can act as Batch protocols, automating intricate analyses while still allowing for manual adjustments. This combination of automation and flexibility drastically reduces the time researchers spend on repetitive tasks, particularly when dealing with large datasets.
Imaris 11 also boasts improved visualization tools that facilitate consistent data representation and cross-dataset comparisons. These enhancements are particularly beneficial for multi-sample experiments, high-content imaging workflows, clinical research, and industrial research and development.
Customer-Centric Approach to Research
According to Anna Paszulewicz, the Imaris Product Manager at Oxford Instruments, “Imaris 11 is a game-changer for researchers. By combining intuitive workflows with powerful automation and data exploration tools, we’re making advanced microscopy image analysis more accessible, efficient, and insightful for research communities across the world.”
Imaris 11 is now available for use, with options for researchers to request a free trial to experience its capabilities firsthand. This launch aligns with the growing demand for innovative solutions in the life sciences and biotechnology sectors, particularly in regions such as Southeast Asia, where streamlined data analysis and improved collaboration are essential for the advancement of research.
About Oxford Instruments
Founded in 1959, Oxford Instruments has established itself as a leader in providing scientific technology and expertise to academic and commercial organizations worldwide. The company operates in key market segments, including Materials Analysis, Healthcare & Life Science, and Semiconductors. With a commitment to innovation, Oxford Instruments aims to accelerate breakthroughs that contribute to a more sustainable and productive future.
As a publicly traded company listed on the FTSE250 index of the London Stock Exchange, Oxford Instruments continues to play a pivotal role in connecting academic researchers with commercial applications, thus driving real-world progress in scientific research and development.
For more information about Imaris 11 or to request a trial, visit Oxford Instruments’ official website.
-
Business5 months agoKenvue Dismisses CEO Thibaut Mongon as Strategic Review Advances
-
Lifestyle4 months agoHumanism Camp Engages 250 Youths in Summer Fest 2025
-
Sports4 months agoDe Minaur Triumphs at Washington Open After Thrilling Comeback
-
Sports5 months agoTupou and Daugunu Join First Nations Squad for Lions Clash
-
Top Stories5 months agoColombian Senator Miguel Uribe Shows Signs of Recovery After Attack
-
World5 months agoASEAN Gears Up for Historic Joint Meeting of Foreign and Economic Ministers
-
Health4 months agoNew Study Challenges Assumptions About Aging and Inflammation
-
Business5 months agoOil Prices Surge Following New EU Sanctions on Russia
-
Entertainment4 months agoDetaşe-Sabah Violin Ensemble Captivates at Gabala Music Festival
-
Entertainment4 months agoBaku Metro Extends Hours for Justin Timberlake Concert
-
Top Stories5 months agoRethinking Singapore’s F&B Regulations Amid Business Closures
-
Business5 months agoU.S. House Approves Stablecoin Bill, Sends to Trump for Signature
